Free Sale Certificates for Thai FDA Medical Device Registration

Of everything that can hold up a medical device registration in Thailand, the Certificate of Free Sale (CFS) is one of the least technical and one of the most consequential. It doesn't require clinical data, biocompatibility testing, or engineering review, but an expired certificate, one issued by the wrong body, or one that hasn't been properly legalized will stop a Class 2, 3, or 4 application at the screening stage before Thai FDA ever looks at the substance of the file. Manufacturers who treat this document as an afterthought routinely lose months to a problem that a five-minute check would have caught.

What the CFS actually proves

Thailand's Medical Device Act B.E. 2551 (2008), as amended in B.E. 2562 (2019), gives the Medical Devices Control Division (MDCD) authority over device registration through the Common Submission Dossier Template (CSDT), a format aligned with the ASEAN Medical Device Directive used across the region. Within that dossier, the CFS does one specific job: it shows Thai FDA that a recognized foreign regulatory authority has reviewed the device, has not prohibited its sale, and knows the manufacturer is exporting it. It's evidence of legal marketing status in the manufacturer's home jurisdiction, and Thai FDA treats it as a threshold screening item rather than a supporting document. A complete, technically strong dossier submitted without a valid CFS still does not advance to substantive review.

Who can actually issue one

Thai FDA insists the CFS come from a government authority: specifically, the national medicines or medical device regulator in the manufacturer's home country. Chamber of commerce letters, industry association certificates, and other third-party attestations are not accepted, no matter how reputable the issuing organization is. In practice, the documents Thai FDA recognizes include the US FDA's Certificate for Foreign Government (CFG), issued through its Export Certificates program; the UK MHRA's Certificate of Free Sale for devices holding UKCA marking or historically CE-marked devices under UK jurisdiction; Health Canada's Certificate of Free Sale through its Medical Devices Bureau; Australia's TGA certificate for devices on the Australian Register of Therapeutic Goods; and CFS-equivalent documents from ASEAN member state regulators including Singapore, Malaysia, Indonesia, the Philippines, and Vietnam.

One distinction manufacturers frequently get wrong: a CE Declaration of Conformity is not a Certificate of Free Sale and cannot substitute for one. CE marking demonstrates conformity with EU technical requirements, but it isn't a government authorization in the sense Thai FDA requires from a CFS. A CE Declaration can support the CSDT as technical documentation, but the CFS requirement stands independently of it.

Timing the certificate against your submission date

Thai FDA requires the CFS to be valid at the time of submission, not merely at the time it was originally obtained, and most national authorities issue these certificates with a validity window of one to two years depending on the country. Because CSDT preparation for a complex device can run several months, sequencing matters: a certificate secured at the start of a long dossier build can expire before the file is actually ready to submit, and an expired CFS is grounds for rejection at screening regardless of how strong the rest of the application is.

The more reliable approach is to work backward from a target submission date rather than forward from the day preparation begins. If a dossier's timeline is genuinely uncertain, it's generally safer to request the CFS later in the process, once the submission window is defined, than to secure it early and risk it lapsing before the file goes in. For devices undergoing renewal or a post-registration variation, an updated CFS reflecting current market status may also be needed; confirming this with MDCD at the time of renewal preparation avoids a surprise later.

Legalization, apostille, and translation

A valid CFS from the correct authority still isn't automatically usable in Thailand until it's been properly authenticated. Thailand deposited its instrument of accession to the Hague Apostille Convention on June 30, 2026, but the Convention will not enter into force for Thailand until February 28, 2027. Until that date, apostille certification cannot be used to authenticate a CFS for Thai FDA purposes, regardless of whether the issuing country is a Hague Convention member. Until entry into force, a full consular legalization chain applies to every CFS: authentication by the relevant ministry in the issuing country, followed by legalization at the Thai embassy or consulate there.

MDCD may also require a certified Thai-language translation of the CFS, prepared by a qualified translator. This isn't enforced on every submission, and application is somewhat discretionary depending on the reviewing officer, but preparing the certified translation upfront during dossier preparation avoids a delay if it's requested after the file is already in.

When no CFS exists, and what applies to Class 1

Not every country runs a formal CFS program, and some regulatory frameworks simply don't produce a discrete document even when the device is legally marketed there. In that situation, Thai FDA may accept an official letter from the relevant national authority confirming the device is legally marketed and its export is not prohibited, subject to the same legalization or apostille requirements as a standard CFS. This is handled case by case, and confirming acceptability with MDCD before the submission is prepared, rather than after, is the only reliable way to avoid a rejection. Manufacturers from jurisdictions with newer regulatory systems, including parts of Asia, Africa, and Latin America, are the ones most likely to run into this and should engage early with both their home regulator and MDCD.

The CFS requirements above apply principally to Class 2, 3, and 4 devices under the full CSDT pathway. Class 1 devices follow a listing route with lighter administrative requirements, and the CFS obligation is correspondingly less strict, though Thai FDA does periodically revise what documentation Class 1 listings need. Confirming current requirements with MDCD before preparing a Class 1 submission is worth doing even when a previous listing didn't require it.

What this means for your dossier

The underlying principle doesn't change across device classes: Thai FDA wants evidence that the device already has regulatory standing in its country of origin, and that evidence has to be current, government-issued, and correctly authenticated for use in Thailand. DeeMED Consulting builds CFS procurement, legalization, and translation into the CSDT dossier preparation timeline for foreign manufacturers from the outset, so the certificate is ready and still valid the day the application actually goes in, not months earlier when the clock started ticking.